4-乙氧基-2-羟基苯甲酸甲酯 | 102232-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基-2-羟基苯甲酸甲酯
• 英文名称: methyl 4-ethoxy-2-hydroxybenzoate
• 英文别名: 4-ethoxy-2-hydroxy-benzoic acid methyl ester；2-Hydroxy-4-aethoxy-benzoesaeure-methylester；4-Aethoxy-2-hydroxy-benzoesaeure-methylester；methyl 4-ethoxysalicylate；2-Hydroxy-4-aethoxybenzoesaeure-methylester
• CAS: 102232-45-1
• 化学式: C₁₀H₁₂O₄
• 分子量: 196.203
• InChiKey: QEHJRVXYYAJULL-UHFFFAOYSA-N

物化性质

• 熔点：
  77-78 °C
• 沸点：
  303.2±22.0 °C(Predicted)
• 密度：
  1.180±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-乙氧基-2-羟基苯甲酸甲酯 在 potassium carbonate 作用下， 以 水 、 丙酮 为溶剂， 生成 2,4-二乙氧基苯甲酸
  参考文献：
  名称：

  呈现两个向列相的棒状液晶的合理设计。

  摘要：

  最近，据报道，一种极性的棒状液晶材料显示出两个不同的向列中间相（称为N和NX），它们被弱的一阶跃迁分开。在本文中，我们介绍了对构成低温向列相的基础的结构-性质关系的初步研究，并报告了几种表现出相同转变的新材料。我们已经准备了具有显着增强的温度范围的材料，从而使我们能够使用小角度X射线散射对高温和低温向列相进行详细研究。我们观察到d间距的连续变化，而不是相变时的急剧变化，这一结果与两个向列相之间的过渡相一致，这两个相的结构可能是简并的。

  DOI：

  10.1002/chem.201702742
• 作为产物：
  描述：

  4-乙氧基-2-羟基苯甲酸 以 甲醇 为溶剂， 生成 4-乙氧基-2-羟基苯甲酸甲酯
  参考文献：
  名称：

  Herbicidal sulfonamides

  摘要：

  本发明涉及某些磺酰脲类除草剂化合物，其农业适用的组合物及其使用方法。

  公开号：

  US04849010A1

文献信息

• Structure-Activity Relationships of Non-peptide Vasopressin V1a Antagonists: 1-(1-Multi-substituted Benzoyl 4-Piperidyl)-3,4-dihydro-2( 1H)-quinolinones.
  作者：Kazumi KONDO、Hidenori OGAWA、Kenji KNAKAYA、Michiaki TOMINAGA、Youichi YABUUCHI

  DOI：10.1248/cpb.44.725

  日期：——

  During our systematic studies on the arginine vasopressin receptor V1a-antagonistic activity of 1-(1-benzoyl substituted 4-piperidyl)-3, 4-dihydro-2(1H)-quinolinones, we found a general substituent effect on the benzene ring. Hydrogen-bonding ability at the ortho position was especially important for enhancement of the affinity of multi-substituted analogs. Details of the syntheses and structuer-activity relationships for this series are presented.

  在我们系统研究一-(1-苯甲酰基代4-哌啶基)-3,4-二氢-2(1H)-喹啉酮类化合物对精氨酸加压素V1a受体的拮抗活性过程中，我们发现了苯环上的一般取代基效应。在邻位上的氢键形成能力对多取代类似物的亲和力增强尤为重要。本文介绍了该系列化合物的合成细节及构效关系。
• Differential effects of UTP and ATP on ion transport in porcine tracheal epithelium
  作者：S K Inglis、R E Olver、S M Wilson

  DOI：10.1038/sj.bjp.0703324

  日期：2000.5

  Isolated segments of porcine tracheal epithelium were mounted in Ussing chambers, current required to maintain transepithelial potential difference at 0 mV (short circuit current, ISC) was monitored and effects of nucleotides upon ISC were studied. Mucosal UTP (100 μM) evoked a transient rise in ISC that was followed by a sustained fall below basal ISC maintained for 30 min. Mucosal ATP (100 μM) also stimulated a transient rise in ISC but in contrast to UTP did not inhibit basal ISC. Submucosal UTP and ATP both transiently increased ISC. UTP‐prestimulated epithelia were refractory to ATP but prestimulation with ATP did not abolish the response to UTP. The epithelia thus appear to express two populations of apical receptors allowing nucleotides to modulate ISC. The UTP‐induced rise was reduced by pretreatment with either bumetanide (100 μM), diphenylamin‐2‐carboxylic acid (DPC, 1 mM), or Cl− and HCO3−‐free solution whilst the fall was abolished by amiloride pretreatment. Thapsigargin (0.3 μM) abolished the UTP‐induced increase in ISC but not the subsequent decrease. Staurosporine (0.1 μM) inhibited basal ISC and blocked UTP‐induced inhibition of ISC. Inhibitors of either protein kinase C (PKC) (D‐erythro sphingosine) or PKA (H89) had no effect. This study suggests that UTP stimulates Cl− secretion and inhibits basal Na+ absorption. ATP has a similar stimulatory effect, which may be mediated by activation of P2Y2 receptors and an increase in [Ca2+]in, but no inhibitory effect, which is likely mediated by activation of a pyrimidine receptor and possible inhibition of a protein kinase other than PKC or PKA. British Journal of Pharmacology (2000) 130, 367–374; doi:10.1038/sj.bjp.0703324

  以下是文本的中文翻译： 将猪气管上皮的分离段放置于尤金箱（Ussing chamber）中，监测维持跨上皮电位差为0 mV所需的电流（短路电流，ISC），并研究核苷酸对ISC的影响。 黏膜侧的UTP（100 μM）引发短暂的ISC上升，随后出现持续30分钟的基线ISC下降。黏膜侧的ATP（100 μM）同样刺激短暂的ISC上升，但与UTP不同，它并未抑制基线ISC。而基底侧的UTP和ATP均短暂增加ISC。 预刺激UTP的上皮对ATP无反应，但以ATP预刺激并不会消除对UTP的反应。这些结果表明，上皮细胞表面存在两组受体，使核苷酸能够调节ISC。 UTP诱导的上升被预先用布美他尼（100 μM）、二苯基氨基-2-羧酸（DPC，1 mM）或无Cl−和HCO3−的溶液处理所抑制，而下降则被预先用阿米洛利处理所消除。 Thapsigargin（0.3 μM）消除了UTP诱导的ISC增加，但未影响随后的下降。Staurosporine（0.1 μM）抑制基线ISC并阻断UTP诱导的ISC抑制。蛋白激酶C（PKC）抑制剂（D-赤藓醇基鞘氨醇）或蛋白激酶A（PKA）抑制剂（H89）均无作用。 本研究表明，UTP刺激Cl−分泌并抑制基线Na+吸收。ATP具有类似的刺激作用，可能是通过激活P2Y2受体和增加[Ca2+]in介导，但无抑制作用，这可能是通过激活嘧啶受体并可能抑制其他蛋白激酶（而非PKC或PKA）。 《英国药理学杂志》 (2000), 130, 367–374; doi:10.1038/sj.bjp.0703324
• Antithrombotic Diamides
  申请人：Franciskovich Jeffry Bernard

  公开号：US20090062271A1

  公开（公告）日：2009-03-05

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本申请涉及公式I化合物（或其药学上可接受的盐），其制药组合物，以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。
• Antithrombotic diamides
  申请人：Eli Lilly and Company

  公开号：US07666866B2

  公开（公告）日：2010-02-23

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本发明涉及公式（I）的化合物（或该化合物的药学上可接受的盐），其制药组合物，以及其作为因子Xa和/或凝血酶的抑制剂的用途，以及其制备方法和中间体。
• Synthesis and Biological Evaluation of <scp>d</scp>-Amino Acid Oxidase Inhibitors
  作者：Dana Ferraris、Bridget Duvall、Yao-Sen Ko、Ajit G. Thomas、Camilo Rojas、Pavel Majer、Kenji Hashimoto、Takashi Tsukamoto

  DOI：10.1021/jm800200u

  日期：2008.6.1

  D-Amino acid oxidase (DAAO) catalyzes the oxidation of D-amino acids including D-serine, a full agonist at the glycine site of the NMDA receptor. A series of benzo[d]isoxazol-3-ol derivatives were synthesized and evaluated as DAAO inhibitors. Among them, 5-chlorobenzo[d]isoxazol-3-ol (CBIO) potently inhibited DAAO with an IC(50) in the submicromolar range. Oral administration of CBIO in conjunction with D-serine enhanced the plasma and brain levels of D-serine in rats compared to the oral administration Of D-serine alone.